VJHemOnc is committed to improving our service to you

VJVirtual | Opportunities to improve CAR-T outcomes

VJHemOnc is committed to improving our service to you

Jordan Gauthier

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, tells us how CAR T-cell therapy responses can be improved, specifically mentioning the humanizing of CAR T-cells to minimize immunogenicity. Dr Gauthier goes on to discuss cytokine-directed therapies such as tocilizumab to minimize the severe toxicities associated with CAR T-cell therapy. He finally goes on to outline how statistical modeling can be harnessed during clinical trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter